A systematic approach for identifying shared mechanisms in epilepsy and its comorbidities

Abstract Cross-sectional epidemiological studies have shown that the incidence of several nervous system diseases is more frequent in epilepsy patients than in the general population. Some comorbidities [e.g. Alzheimer’s disease (AD) and Parkinson’s disease] are also risk factors for the development of seizures; suggesting they may share pathophysiological mechanisms with epilepsy. A literature-based approach was used to identify gene overlap between epilepsy and its comorbidities as a proxy for a shared genetic basis for disease, or genetic pleiotropy, as a first effort to identify shared mechanisms. While the results identified neurological disorders as the group of diseases with the highest gene overlap, this analysis was insufficient for identifying putative common mechanisms shared across epilepsy and its comorbidities. This motivated the use of a dedicated literature mining and knowledge assembly approach in which a cause-and-effect model of epilepsy was captured with Biological Expression Language. After enriching the knowledge assembly with information surrounding epilepsy, its risk factors, its comorbidities, and anti-epileptic drugs, a novel comparative mechanism enrichment approach was used to propose several downstream effectors (including the GABA receptor, GABAergic pathways, etc.) that could explain the therapeutic effects carbamazepine in both the contexts of epilepsy and AD. We have made the Epilepsy Knowledge Assembly available at https://www.scai.fraunhofer.de/content/dam/scai/de/downloads/bioinformatik/epilepsy.bel and queryable through NeuroMMSig at http://neurommsig.scai.fraunhofer.de. The source code used for analysis and tutorials for reproduction are available on GitHub at https://github.com/cthoyt/epicom.

[1]  Florence Pasquier,et al.  Phenotype associated with APP duplication in five families. , 2006, Brain : a journal of neurology.

[2]  Steven Petrou,et al.  The Mechanism of Carbamazepine Aggravation of Absence Seizures , 2006, Journal of Pharmacology and Experimental Therapeutics.

[3]  K. Staley Molecular mechanisms of epilepsy , 2015, Nature Neuroscience.

[4]  Woong Sun,et al.  Early growth response 1 (Egr‐1) directly regulates GABAA receptor α2, α4, and θ subunits in the hippocampus , 2015, Journal of neurochemistry.

[5]  Martin Hofmann-Apitius,et al.  Mining biomarker information in biomedical literature , 2012, BMC Medical Informatics and Decision Making.

[6]  Charles Tapley Hoyt,et al.  PyBEL: a computational framework for Biological Expression Language , 2017, Bioinform..

[7]  H. Steiner,et al.  Genes and mechanisms involved in β-amyloid generation and Alzheimer’s disease , 1999, European Archives of Psychiatry and Clinical Neuroscience.

[8]  R. Connors,et al.  Evidence for a shared genetic susceptibility to migraine and epilepsy , 2013, Epilepsia.

[9]  P. Tariot,et al.  Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. , 1998, The American journal of psychiatry.

[10]  Ted Slater,et al.  Recent advances in modeling languages for pathway maps and computable biological networks. , 2014, Drug discovery today.

[11]  R Bellazzi,et al.  Big Data and Biomedical Informatics: A Challenging Opportunity , 2014, Yearbook of Medical Informatics.

[12]  J R Storey,et al.  Topiramate in Migraine Prevention: A Double‐Blind, Placebo‐Controlled Study , 2001, Headache.

[13]  Filippo S. Giorgi,et al.  The role of norepinephrine in epilepsy: from the bench to the bedside , 2004, Neuroscience & Biobehavioral Reviews.

[14]  Moran Gal,et al.  Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells. , 2003, Gene.

[15]  Yaakov Stern,et al.  Incidence and Predictors of Seizures in Patients with Alzheimer's Disease , 2006, Epilepsia.

[16]  M. Doran,et al.  Clinical phenotypic heterogeneity of Alzheimer's disease associated with mutations of the presenilin–1 gene , 2006, Journal of Neurology.

[17]  R. S. Jones,et al.  The action of anticonvulsant drugs on the firing of locus coeruleus neurons: selective, activating effect of carbamazepine. , 1983, European journal of pharmacology.

[18]  Run Wang,et al.  Evaluating the Effectiveness of GTM-1, Rapamycin, and Carbamazepine on Autophagy and Alzheimer Disease , 2017, Medical science monitor : international medical journal of experimental and clinical research.

[19]  Sang Hong Lee,et al.  Estimation of pleiotropy between complex diseases using single-nucleotide polymorphism-derived genomic relationships and restricted maximum likelihood , 2012, Bioinform..

[20]  Josemir W Sander,et al.  Effects of topiramate on cognitive function , 2000, Journal of neurology, neurosurgery, and psychiatry.

[21]  Josemir W Sander,et al.  Comorbidities of epilepsy: current concepts and future perspectives , 2016, The Lancet Neurology.

[22]  L. Mucke,et al.  Epilepsy and cognitive impairments in Alzheimer disease. , 2009, Archives of neurology.

[23]  S. Masino,et al.  Adenosine receptors and epilepsy: current evidence and future potential. , 2014, International review of neurobiology.

[24]  Francisco Sales,et al.  Ontology and Knowledge Management System on Epilepsy and Epileptic Seizures , 2010, SWAT4LS.

[25]  M. Solas,et al.  Treatment Options in Alzheimer´s Disease: The GABA Story. , 2015, Current pharmaceutical design.

[26]  Mohammad Asif Emon,et al.  Multimodal mechanistic signatures for neurodegenerative diseases (NeuroMMSig): a web server for mechanism enrichment , 2017, Bioinform..

[27]  Martin Hofmann-Apitius,et al.  Computable cause-and-effect models of healthy and Alzheimer's disease states and their mechanistic differential analysis , 2015, Alzheimer's & Dementia.

[28]  Dietmar R. Thal,et al.  Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years , 2011, Journal of neuropathology and experimental neurology.

[29]  A. Algra,et al.  Cognitive impairment in tuberous sclerosis complex is a multifactorial condition , 2008, Neurology.

[30]  B. Scatton,et al.  Modulation of the gamma-aminobutyric acid type A receptor by the antiepileptic drugs carbamazepine and phenytoin. , 1995, Molecular pharmacology.

[31]  Samuel Wiebe,et al.  Somatic Comorbidity of Epilepsy in the General Population in Canada , 2005, Epilepsia.

[32]  John F Rothrock Topiramate for Migraine Prevention: An Update , 2012, Headache.

[33]  Patrício Soares-da-Silva,et al.  Mechanisms of Action of Carbamazepine and Its Derivatives, Oxcarbazepine, BIA 2-093, and BIA 2-024 , 2002, Neurochemical Research.

[34]  Qiang Lu,et al.  A polymorphism in CALHM1 is associated with temporal lobe epilepsy , 2011, Epilepsy & Behavior.

[35]  W. Le,et al.  Autophagy enhancer carbamazepine alleviates memory deficits and cerebral amyloid-β pathology in a mouse model of Alzheimer's disease. , 2013, Current Alzheimer research.

[36]  Martin Hofmann-Apitius,et al.  Towards a Pathway Inventory of the Human Brain for Modeling Disease Mechanisms Underlying Neurodegeneration. , 2016, Journal of Alzheimer's disease : JAD.

[37]  Jeffrey Noebels,et al.  A perfect storm: Converging paths of epilepsy and Alzheimer’s dementia intersect in the hippocampal formation , 2011, Epilepsia.

[38]  Clementina Boniver,et al.  Comorbidity between headache and epilepsy in a pediatric headache center , 2010, The Journal of Headache and Pain.

[39]  M. Murphy,et al.  Alzheimer's disease and the amyloid-beta peptide. , 2010, Journal of Alzheimer's disease : JAD.

[40]  Richard W Newton,et al.  The underlying etiology of infantile spasms (West syndrome): Information from the United Kingdom Infantile Spasms Study (UKISS) on contemporary causes and their classification 2 , 2010, Epilepsia.

[41]  Sonia Maria Dozzi Brucki,et al.  Epilepsy in patients with Alzheimer's disease: A systematic review , 2014, Dementia & neuropsychologia.

[42]  James B Leverenz,et al.  Alzheimer's disease phenotypes and genotypes associated with mutations in presenilin 2. , 2010, Brain : a journal of neurology.

[43]  Detlev Boison,et al.  Adenosine and Seizure Termination: Endogenous Mechanisms , 2013, Epilepsy currents.

[44]  R. Altman,et al.  Pharmacogenomics Knowledge for Personalized Medicine , 2012, Clinical pharmacology and therapeutics.

[45]  J. H. Cross,et al.  ILAE Official Report: A practical clinical definition of epilepsy , 2014, Epilepsia.

[46]  Guojun Bu,et al.  Implications of GABAergic Neurotransmission in Alzheimer’s Disease , 2016, Front. Aging Neurosci..

[47]  Josemir W Sander Comorbidity and premature mortality in epilepsy , 2013, The Lancet.

[48]  Dulaney A Wilson,et al.  Epilepsy beyond seizure: A population-based study of comorbidities , 2014, Epilepsy Research.

[49]  Tim Pearson,et al.  Adrenoceptor subtype‐specific acceleration of the hypoxic depression of excitatory synaptic transmission in area CA1 of the rat hippocampus , 2004, The European journal of neuroscience.

[50]  D. Treiman GABAergic Mechanisms in Epilepsy , 2001, Epilepsia.

[51]  Bruce Hermann,et al.  Association of epilepsy and comorbid conditions. , 2009, Future neurology.

[52]  Peter Mariën,et al.  Cerebellar cognitive affective syndrome associated with topiramate , 2008, Clinical Neurology and Neurosurgery.